

Press Release

Stockholm, October 23, 2000

Biolin Medical increases ownership in Integration Diagnostics

Biolin Medical has increased the ownership in Integration Diagnostics Ltd that has developed and sells Osstell™, a system for measuring dental implant stability. The international launch of Osstell™ has recently started and the product has received a very positive response from leading implantologists and opinion formers all over the world.

"We increase our commitment in the company and expect to see a strong growth in sales over the next couple of years", says Per Spångberg, CEO of Biolin Medical.

"The company has a strong position in the market through the possibility to contribute to substantial reductions in treatment-periods for dental implants – something that patients and dentists have demanded for quite some time", he adds.

Osstell™, based upon a unique technology for measuring resonance frequency, has been developed at Imperial College in London. The system consists of an instrument, a transducer and software. An approval to sell the system on the US market is expected during the first quarter of 2001.

"Through the increased commitment from our main owner, Biolin Medical, we have the opportunity to begin a focused commercialization of the company. We have had a great response from the market and we know that Osstell™ works well and is in demand all over the world. We concentrate our resources to Europe during this year and plan to launch Osstell™ in the US during 2001", says Anders Petersson, CEO of Integration Diagnostics.

For further information:

Per Spångberg, CEO Biolin Medical AB, +46 8 679 90 10 or +46 70 485 26 39
Anders Petersson, CEO Integration Diagnostics Ltd, +46 31 340 94 48 or
+46 70 974 12 69

Biolin Medical is a venture-capital company that creates value growth in high-technology companies in biotech, medical technology and related areas. Through an operative owner commitment based on unique competence and a comprehensive network, Biolin develops innovations for commercial companies. Bolin's investment portfolio consists of ownership in the companies AlcoDia, Biovator, Boule Diagnostics, BST Blood Saving Technologies, Cavid Tech, Integration Diagnostics, Q-Sense and Sinterkil.